Expert opinion on emerging drugs for lung chronic graft-versus-host disease-Reference-Cited by-同舟云学术

Expert opinion on emerging drugs for lung chronic graft-versus-host disease

Published:2022-04-03 Issue:2 Volume:27 Page:99-101
ISSN:1472-8214
Container-title:Expert Opinion on Emerging Drugs
language:en
Short-container-title:Expert Opinion on Emerging Drugs

Author:

Gabrielli Giulia¹²,Dogliotti Irene¹,Mangiapia Mauro³,Chiappero Chiara³,Gill Jessica¹²,Dellacasa Chiara Maria¹,Busca Alessandro¹,Giaccone Luisa¹²

Affiliation:

1. Stem Cell Transplant Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

2. Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

3. Pneumology Unit, Department of cardiovascular and thoracic diseases, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728214.2022.2089651

Reference15 articles.

1. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report

2. Negative impact of chronic graft-versus-host disease and glucocorticoid on the recovery of physical function after allogeneic hematopoietic stem cell transplantation

3. Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease

4. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

5. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD